Navigation Links
VENENUM Biodesign to Exhibit at SBS
Date:3/22/2011

HAMILTON, N.J., March 22, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today that it will be exhibiting at the 17th SBS Annual Conference & Exhibition at the Gaylord Palms Resort and Convention Center in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will be exhibiting at booth #524.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign Compound Collection, which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department, which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "VENENUM is well-positioned with full ranging 'Gene to Lead' capabilities in early drug discovery to partner with pharma and non-profits. We are actively seeking those collaborations. VENENUM is also working to identify hits against novel targets and advance these through our Medicinal Chemistry."

To find out more, please visit http://www.venenumbiodesign.com.

Contact:

Maria Webb, Ph.D.
Chief Scientific Officer (CSO)
mwebb@venenumbiodesign.com
877.950.1032
http://www.venenumbiodesign.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VENENUM Biodesign
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
2. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposiumâ„¢
3. Nanowires exhibit giant piezoelectricity
4. At RSNA, DR Systems Will Exhibit New Unity v-Series Web PACS
5. WAVE Conference and Exhibition 2011 Taking Products to Market incorporating Micro & Nano Technology
6. Graphene exhibits bizarre new behavior well suited to electronic devices
7. Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York
8. PRA International Exhibits at European Hematology Association Congress
9. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
10. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
11. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Ca (PRWEB) , ... April 19, 2017 , ... ... Virtual Event, which makes educational webinars accessible to novices as well as ... of preanalytical variables of commonly performed coagulation screening tests. , Hemostasis testing ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 ... specialty finance firm that provides senior debt to ... the closing of a $20 million senior secured ... orthobiologics company engaged in the development and commercialization ... of orthopedic injuries. Cerapedics, lead product, ...
(Date:4/18/2017)... Urdorf, Switzerland (PRWEB) , ... April 18, 2017 ... ... a smartphone/tablet app that converts conductivity readings to concentration levels and vice-versa. , ... analytical chemistry is analyzing solution strength in concentration control or monitoring. The principle ...
(Date:4/18/2017)... ... April 18, 2017 , ... Whitehouse Laboratories ... East. MD&M East has helped take medical devices from concept to market ... foremost minds. , Whitehouse labs will showcase its diverse and comprehensive capabilities which ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):